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Abstract
Background: Neuroendocrine carcinoma is an aggressive neoplasm that mainly affects elderly
Caucasians and typically arises in sun-exposed areas of the skin. The disease is rather rare and only
a relatively few cases present with no apparent primary lesion.
Case presentation: We report a case of an 81-year-old Caucasian male with neuroendocrine
carcinoma, which initially presented as a large retroperitoneal mass. Pathological and
immunohistochemical analysis of the transabdominal CT-guided biopsy specimen revealed tissue
consistent with neuroendocrine carcinoma. The patient underwent exploratory laparotomy and
the mass was successfully excised along with an associated mesenteric lymph node.
Discussion: There are currently two possible explanations for what occurred in our patient. First,
the retroperitoneal mass could be a massively enlarged lymph node where precursor cells became
neoplastic. This would be consistent with a presumptive diagnosis of primary nodal disease.
Alternatively, an initial skin lesion could have spontaneously regressed and the retroperitoneal
mass represents a single site of metastasis. Since Merkel cell precursors have never been identified
within lymph nodes, the latter theory seems more befitting. Moreover, metastasis to the
retroperitoneal lymph nodes has been reported as relatively common when compared to other
sites such as liver, bone, brain and skin.
Conclusion: Wide local excision of the primary tumor is the surgical treatment of choice for
localized disease. We propose that further studies are needed to elucidate the true efficacy of
chemotherapy in conventional as well as unconventional patients with neuroendocrine carcinoma.
Background
Neuroendocrine carcinoma, also known as Merkel cell
carcinoma, is an aggressive neoplasm that mainly affects
elderly Caucasians and typically arises in sun-exposed
areas of the skin. In this report, we examine a rare case of
neuroendocrine carcinoma, which initially presented as a
retroperitoneal mass. After extensive workup, no primary
site was identified in the skin or elsewhere. Relatively few
cases present with no apparent primary lesion.
Case presentation
An eighty-one year old Caucasian male presented in June
2006 to the Emergency Department of the Brooklyn Hos-
pital Center with a one-month history of blood- tinged
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stools. He was admitted to the medical service for further
management. The surgical team was consulted for evalua-
tion of pain associated with a palpable mass in the right
iliac fossa. The pain was described as dull, non-radiating
and constant in nature. It was rated a 3 on a 10-point
intensity scale and there were no reported exacerbating or
ameliorating factors. The patient's history was significant
for intermittent constipation and repair of an incarcerated
umbilical hernia three weeks prior.
On examination, vital signs were normal. The abdomen
was non-distended with a 3-cm, midline, infraumbilical
scar. Tenderness was noted on deep palpation of the right
lower quadrant and a large mass was felt measuring
approximately 5-cm × 5-cm. The lower margin could not
be felt. The mass was also palpable on digital rectal exam.
Femoral pulses were normal. Laboratory values were
unremarkable. Fecal occult blood test was negative.
Colonoscopy showed the cecum high in the right upper
quadrant with no evidence of a cecal mass. Contrast com-
puted tomography (CT) of both abdomen and pelvis (Fig-
ure 1) revealed a 5-cm × 5-cm × 7.5-cm, enhancing,
rounded, heterogeneous, well-defined mass in the right
lower quadrant, ventral to the psoas muscle and displac-
ing the terminal ileum anteriorly.
Chest X-ray was unremarkable. Magnetic resonance imag-
ing (MRI) of the pelvis (Figure 2) confirmed CT findings
and showed that the mass abutted and compressed the
external iliac vessels. Pseudoaneurysm was ruled out. Gal-
lium and positron emission tomography (PET) scans (Fig-
ure 3) revealed localized abnormal activity in the right
lower quadrant. Octreoscan showed a solitary, abnormal
lesion in the lower right quadrant consistent with previ-
ous findings. No other lesions, primary or metastatic,
were demonstrated in any of these studies. Meticulous
physical examination of the skin and lymph nodes also
revealed no suspicious lesions. There was no evidence of
appendicitis and biopsy was recommended. Exhaustive
pathological and immunohistochemical analysis of the
transabdominal CT-guided biopsy specimen (Figure 4)
revealed that tumor cells were positive for both synapto-
physin and CK 20, but negative for TTF-1, CK7, WT-1,
HBME-1, CD45, CD20, CD3, PAP, PSA, S100 and HMB-
45. With such a staining profile, a definitive diagnosis of
neuroendocrine (Merkel cell) carcinoma was made and
we chose to forego further analysis.
The patient then underwent exploratory laparotomy and
the mass was successfully excised along with an associated
mesenteric lymph node. Final pathologic analysis of the
mass was consistent with biopsy findings and the
mesenteric lymph node was negative for tumor. Extuba-
tion was delayed due to difficult intubation and the
patient was transferred to the surgical intensive care unit
for observation. He was extubated the following day and
transferred to the surgical floor where he had an unevent-
ful recovery and was discharged on postoperative day
eight. The patient's care was then transferred to an oncol-
ogist at another institution where he is currently being
monitored and evaluated for treatment with various
chemotherapeutic regimens.
Discussion
Neuroendocrine carcinoma is an aggressive, usually cuta-
neous neoplasm with a propensity for metastasis. The
MRI of pelvis showing right lower quadrant mass compress- ing external iliac vessels Figure 2
MRI of pelvis showing right lower quadrant mass compress-
ing external iliac vessels.
CT scan of pelvis showing right lower quadrant mass Figure 1
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tumor mainly affects elderly Caucasians. Although it is
widely referred to as Merkel cell carcinoma, the term neu-
roendocrine carcinoma of the skin is more appropriate
due to the tumor's histologic and histochemical character-
istics [1]. The disease is rather rare with an annual inci-
dence ranging from 0.2 to 0.45 cases per 100,000 [2-4]. In
a review of 661 cases conducted in 2000, only 2 percent
presented with no apparent primary lesion [5]. However,
in a later, but smaller series, 19% of those with nodal neu-
roendocrine tumors had no detectable primary site [6].
Merkel cells reside in the basal layer and hair follicles of
the skin's epidermis and are associated with mechanore-
ceptors in the dermal papillae [7]. It has been proposed
that neuroendocrine carcinoma of the skin arises from
these cells. However, since it is mainly a dermal tumor, an
alternative hypothesis that they originate from immature
totipotent stem cells and acquire neuroendocrine charac-
teristics upon malignant transformation [1,8,9] is perhaps
more plausible. The occasional presence of squamous or
eccrine differentiation in these tumors also suggests stem-
cell origin [10].
Sun exposure is thought to play a major role in pathogen-
esis, but some cases present with lesions in non-sun-
exposed areas. In our case, sun-exposure seems to have
played no role, as the tumor apparently did not even
involve the skin. Immunosuppression can also predispose
to the disease, but it was not a factor in this case since the
patient was not immunosuppressed. There are currently
two possible explanations [1,11-13] for what occurred in
our patient. First, the retroperitoneal mass could be a mas-
sively enlarged lymph node where precursor cells became
neoplastic. This would be consistent with a presumptive
diagnosis of primary nodal disease. Alternatively, an ini-
tial skin lesion could have spontaneously regressed and
the retroperitoneal mass represents a single site of metas-
tasis. Since Merkel cell precursors have never been identi-
fied within lymph nodes, the latter theory seems more
befitting. Moreover, metastasis to the retroperitoneal
lymph nodes has been reported as relatively common
when compared to other sites such as liver, bone, brain
and skin [9].
It is difficult to accurately diagnose neuroendocrine carci-
noma due to its similarity to other poorly differentiated
"small blue cell tumors" like small cell carcinoma of the
lung [14]. Histopathologic differentiation techniques are
necessary for definitive diagnosis. When found, perinu-
clear keratin filaments on electron microscopy and a dot-
like pattern with cytokeratin (CK) 20 and CK 7 staining
aid in diagnosis [15-17].
Staging is done according to criteria developed by the
Memorial Sloan-Kettering Cancer Center [18]. Stage I
describes node-negative disease with a tumor less than 2-
cm in size. Node-negative disease with tumors equal to or
greater than 2-cm in size is classified as Stage II. Stage III
represents nodal metastasis and stage IV represents distant
metastasis. Workup for staging includes chest radiograph
to rule out small cell lung cancer and CT scan of the chest
and abdomen.
In 2005, Allen et al reported five-year disease-specific sur-
vival for patients with neuroendocrine carcinoma to be
64% [18]. In 2006, Clark et al found disease-specific sur-
vival at five years to be 49% and overall survival at five
years to be 62% [11]. In most cases, these tumors are
aggressive and have a high rate of metastasis and recur-
rence. Survival rates for patients with disease beyond the
primary lesion are comparable to those of patients with
Microscopic examination reveals tumor composed of monot- onous round cells showing scant eosinophilic cytoplasmic  rim, round and vesicular nuclei with finely granular and dusty  chromatin and multiple nucleoli (A, hematoxylin and eosin  ×100) Figure 4
Microscopic examination reveals tumor composed of monot-
onous round cells showing scant eosinophilic cytoplasmic 
rim, round and vesicular nuclei with finely granular and dusty 
chromatin and multiple nucleoli (A, hematoxylin and eosin 
×100). Tumor cells are positive for synaptophysin (B, ×100) 
and CK 20 (C, ×100).
Gallium scan showing right lower quadrant enhancement Figure 3
Gallium scan showing right lower quadrant enhancement.Publish with BioMed Central    and   every 
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malignant melanoma, nodal spread being the best predic-
tor of distant metastatis or death [18]. Primary nodal neu-
roendocrine carcinoma follows a less aggressive course
than the metastatic form of nodal involvement [19]. Thus,
follow-up of patients may provide insight into whether
nodal disease was primary or metastatic.
The aggressive nature of this disease necessitates frequent
follow-up. The presence of risk factors including tumors
larger than 2-cm, truncal location, male sex, age over 65,
nodal or distant disease at presentation and duration of
disease before presentation [5] should determine the
appropriate frequency. On examination, the clinician
should focus on the lymphatic and integumentary sys-
tems. When symptoms lead to suspicion of recurrence,
appropriate imaging studies should be performed.
Conclusion
Wide local excision of the primary tumor is the surgical
treatment of choice for localized disease. This approach
along with nodal dissection and locoregional irradiation
in clinically node-positive patients or elective lymph node
resection in clinically node-negative patients has been
associated with both decreased rate of and longer interval
to recurrence. The value of chemotherapy is still undeter-
mined [20]. Thus, our patient received none. Since our
patient's tumor could have originated from a lymph node,
six weeks of loco-regional irradiation was administered
following wide local excision. We propose that further
studies are needed to elucidate the true efficacy of chemo-
therapy in patients with conventional as well as uncon-
ventional presentations of neuroendocrine carcinoma.
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